Invex Therapeutics is a biopharmaceutical company that specializes in repurposing an existing drug, Exenatide, for the treatment of neurological conditions caused by, or related to, raised intracranial pressure. The company focuses on conditions such as Idiopathic Intracranial Hypertension (IIH), acute stroke, and traumatic brain injury. It has trademarked its repurposed Exenatide as Presendin™.